Community Research and Development Information Service - CORDIS

New therapeutic pathways for diabetes

The pharmaceutical industry is constantly on the lookout for novel therapeutics, with increased efficacy and fewer side-effects compared to existing treatments.
New therapeutic pathways for diabetes
This also holds true in the case of type II diabetes and also CNS disorders. The glycogen synthase kinase 3 (GSK-3) enzyme has been identified as a key therapeutic target for the development of novel compounds that can act against type II diabetes and several CNS disorders. The Israeli researchers involved in the research project have shown that GSK-3 inhibitors can display high specificity and an improved toxicity profile, compared to marketed drugs.

GSK-3 modulates insulin activity and its activity is elevated in insulin resistant and type II diabetic tissues. Researchers developed a number of novel inhibitors against GSK-3 from which specific leads were selected. For one of those leads, in vitro studies revealed a favourable toxicity profile even at high doses. The specific structure of that compound was used as the starting point for the synthesis of a number of compounds.

The overall lead compound, GSC-7 was shown to improve glucose tolerance and decrease fatty deposits in the liver. Furthermore, GSK-3 inhibitors like GSC-7 could also find application in the treatment of a number of neurological disorders including Alzheimer's disease.

The researchers are now seeking to outlicense their technology to a suitable partner with sufficient development capabilities both at the preclinical and clinical development stages.
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top